| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.04.29 | 100.00 | 4.310 | 4.280 | 429.61 | | 2025.04.28 | 100.00 | 4.400 | 4.340 | 437.24 | | 2025.04.25 | 100.00 | 4.390 | 4.300 | 434.61 | | 2025.04.24 | 100.00 | 4.300 | 4.240 | 428.32 | | 2025.04.16 | 100.00 | 4.460 | 4.370 | 441.02 | | 2025.04.15 | 150.00 | 4.400 | 4.350 | 656.50 | | 2025.04.14 | 150.00 | 4.400 | 4.350 | 655.73 | | 2025.04.11 | 49.00 | 4.370 | 4.360 | 214.13 | | 2025.04.10 | 150.00 | 4.300 | 4.2 ...

Core Viewpoint - Mengniu Dairy has been actively repurchasing its shares, indicating a strategy to enhance shareholder value and confidence in its stock performance [2] Summary by Category Share Buyback Activity - On April 29, Mengniu Dairy repurchased 200,000 shares at a price range of HKD 18.940 to HKD 19.200, totaling HKD 3.8077 million [2] - The stock closed at HKD 19.020 on the same day, reflecting a decrease of 0.31% with a total trading volume of HKD 193 million [2] - Year-to-date, the company has conducted 15 buybacks, acquiring a total of 3.89 million shares for a cumulative amount of HKD 67.5025 million [2] Detailed Buyback Information - The buyback details are as follows: - April 29: 20,000 shares at a maximum price of HKD 19.200 and a minimum of HKD 18.940, amounting to HKD 3.8077 million - April 25: 20,000 shares at a maximum price of HKD 19.300 and a minimum of HKD 19.160, amounting to HKD 3.8495 million - April 24: 20,000 shares at a maximum price of HKD 19.200 and a minimum of HKD 19.120, amounting to HKD 3.8337 million - April 22: 30,000 shares at a maximum price of HKD 19.300 and a minimum of HKD 19.100, amounting to HKD 5.7650 million - April 17: 20,000 shares at a maximum price of HKD 19.500 and a minimum of HKD 19.460, amounting to HKD 3.8957 million - April 8: 15,000 shares at a maximum price of HKD 18.900 and a minimum of HKD 18.700, amounting to HKD 2.8225 million - April 7: 80,000 shares at a maximum price of HKD 17.980 and a minimum of HKD 17.640, amounting to HKD 14.2882 million - January 16: 46,000 shares at a maximum price of HKD 14.980 and a minimum of HKD 14.860, amounting to HKD 6.8767 million - January 10: 13,000 shares at a maximum price of HKD 15.320 and a minimum of HKD 15.280, amounting to HKD 1.9906 million - January 9: 12,000 shares at a maximum price of HKD 16.040, amounting to HKD 1.9248 million - January 8: 30,000 shares at a maximum price of HKD 16.100 and a minimum of HKD 16.060, amounting to HKD 4.8262 million - January 7: 18,000 shares at a maximum price of HKD 16.440 and a minimum of HKD 16.240, amounting to HKD 2.9470 million - January 6: 30,000 shares at a maximum price of HKD 16.260 and a minimum of HKD 16.200, amounting to HKD 4.8710 million - January 3: 18,000 shares at a maximum price of HKD 16.400 and a minimum of HKD 16.340, amounting to HKD 2.9472 million - January 2: 17,000 shares at a maximum price of HKD 17.020 and a minimum of HKD 16.680, amounting to HKD 2.8567 million [2]

Core Viewpoint - The company has shown steady operational improvement in Q1 2025, with significant increases in revenue and profit compared to the same period last year Group 1: Financial Performance - The company's revenue increased by approximately 16.1% year-on-year for the three months ending March 31, 2025, while profit rose by about 14.3% [1] - Profit attributable to ordinary shareholders increased by approximately 16.7% compared to the same period last year [1] Group 2: Comprehensive Medical Services - The company has focused on improving the quality and efficiency of comprehensive medical services amidst external challenges such as payment reforms and strict management of medical insurance funds [1] - The overall operational status of the company's medical institutions was good, with outpatient and emergency visits increasing by about 2.3% year-on-year [1] - The average length of hospital stay decreased to 9.2 days, indicating improved operational efficiency [1] - Medical service revenue accounted for 35.6% of total revenue, up by 2.5 percentage points year-on-year, reflecting an optimized revenue structure [1] - The proportion of drug costs to revenue decreased from 46.5% to 43.7%, demonstrating effective cost control [1] Group 3: Specialized Medical and Health Technology - The company is pursuing a dual strategy of intrinsic development and external expansion in specialized medical and health technology [2] - The acquisition of Beijing Jinxu Medical Instrument Co., Ltd. was completed, enhancing the company's capabilities in medical endoscopy and related services [2] - This acquisition addresses challenges related to high asset values and maintenance costs in the company's managed services for medical endoscopes [2] - The company has expanded its market presence and improved its integration with regional governments following the acquisition of Shandong Qingniao Soft Communication Co., Ltd. [2] Group 4: Financial Business - The company is committed to serving the real economy and advancing its financial business transformation [3] - It is transitioning towards four key areas: health and wellness, equipment manufacturing, chemical pharmaceuticals, and innovative businesses [3] - The company has introduced a new model combining "financing leasing + full lifecycle management" for medical equipment [3] - The company has effectively controlled overall financing costs while ensuring adequate liquidity and stable debt structure [3] - As of March 31, 2025, the total interest-earning assets have continued to grow, with stable improvements in net interest margin and net profit margin [3]

智通财经APP获悉，4月30日，云顶新耀(01952)今日宣布，中国香港卫生署已正式批准伊曲莫德 (VELSIPITY®，etrasimod)用于治疗中重度活动性溃疡性结肠炎(UC)成人患者的新药上市许可申请。继 中国澳门和新加坡之后，中国香港成为伊曲莫德在云顶新耀授权区域内第三个获批的地区。2024年12 月，伊曲莫德(维适平TM)的新药上市申请获得中国国家药品监督管理局的正式受理。 伊曲莫德是一款每日一次口服的一线先进疗法，不仅使用方便、疗效佳，而且具有良好的安全性特征。 此次获批是基于ELEVATE UC III期注册研究(ELEVATE UC 52和ELEVATE UC 12)的结果。这两项随 机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点，安全性特征与既往研究一致。此前，伊 曲莫德已被纳入2024年美国胃肠病学协会(AGA)临床实践指南, 作为溃疡性结肠炎的一线治疗。 云顶新耀首席执行官罗永庆表示："非常高兴看到伊曲莫德的新药上市申请在中国香港获批。2022年， 中国的溃疡性结肠炎患者数量约为60万人，预计到2030年将达到100万人，存在迫切且巨大的未被满足 的临床需求。我们始终致力于提升 ...

不俗的业绩表现，让阳光保险在资本市场也颇受青睐。进入2025年以来股价由2.75港元涨至4月27日收盘的3.50港元，涨幅达27.2%。一举扭转2024年全年 股价下跌35%的局面，作为一家国内知名民营保险服务集团，阳光保险自2022年12月9日上市后，股价就一路走低，长期在低位徘徊，相较上市发行价 5.83港元，下跌40%，市值蒸发超200亿港元。但进入2025年其股价明显回暖。截至4月27日收盘，阳光保险最新市值为402.6亿港元。 | | 今开:3.480 最高:3.620 成交量:857.5万 内盘: | | --- | --- | | 阳光保险 06963.hk 3.5004 +0.020 +0.575% | 昨收:3.480 最低:3.450 成交额:3011万 外盘: | 近期#阳光保险董事长拉员工开会到凌晨#话题登上热搜，引发网友热议。 同期中国人寿市值为1.032万亿元，中国平安市值9437亿元，中国人保市值3184亿元，中国太保市值2965亿元……在2024年《财富》中国500强榜单中，阳 光保险位列第313位，较上年提升明显，整体实力和头部险企差距较大。 阳光保险近日内部发通知称，张维功 ...

Core Viewpoint - The company, Xintian Green Energy, has released its first quarter report for 2025, highlighting significant changes in operational metrics and financial data, while ensuring the accuracy and completeness of the information provided [1][12][16]. Financial Data Summary - The first quarter financial report is not audited [2]. - The company reported a total power generation of 4,544,188.70 MWh, an increase of 10.37% year-on-year [8]. - The total on-grid electricity reached 4,442,621.49 MWh, reflecting a year-on-year increase of 10.45% [8]. - The average on-grid electricity price (excluding tax) was 0.43 RMB/kWh, unchanged from the previous year [8]. - Market-based electricity trading volume was 1,986,200.29 MWh, with a trading volume ratio of 44.71%, up by 9.04 percentage points year-on-year [8]. Gas Transmission and Sales Summary - The total gas transmission/sales volume was 184,698.01 million cubic meters, a decrease of 17.18% year-on-year [9]. - The sales volume was 168,417.04 million cubic meters, down by 15.23% year-on-year [9]. - The gas transmission volume was 16,280.97 million cubic meters, showing a significant decrease of 33.13% year-on-year [9]. Shareholder Information - As of March 31, 2025, the total number of shareholders was 43,628, with 42,490 A-share shareholders and 1,138 H-share shareholders [3]. Board and Supervisory Meetings - The board of directors held a meeting on April 29, 2025, where the first quarter report was approved unanimously [11][12]. - The supervisory board also convened on the same day and approved the first quarter report, confirming its compliance with legal and regulatory requirements [14][16].

金十数据4月30日讯，融创服务(01516.HK)公告，为进一步优化战略布局，将更多资源与管理精力聚焦 投入在一二线核心城市，于2025年4月29日，本公司之全资附属公司融远投资与广西老彰家等订立股权 交易协议，以实现本集团全面退出彰泰服务集团。据此，融远投资将其间接持有的广西彰泰融创智慧 80%股权，以代价人民币8.2662亿元，通过相关交易安排转让给广西老彰家。本次交易完成后，本集团 将不再持有彰泰服务集团任何权益。 融创服务：以8.26亿元出售彰泰融创智慧80%股权 ...

Group 1 - The core revenue for ASMPT in the first quarter was 3.12 billion HKD, slightly below the forecast of 3.2 billion HKD [1] - The net profit for the first quarter was reported at 83.6 million HKD [1]

友邦保险集团首席执行官兼总裁李源祥表示： "我们经验丰富的管理团队致力构建长远、可持续的优质业务，并继续专注于执行我们的策略性优先任 务，让集团能够在环球资本市场波动的环境下取得佳绩，并把握亚洲这个全球最具吸引力的人寿及健康 保险市场的强劲基本增长动力。本人深信，友邦保险凭借雄厚的竞争优势，将继续为所有持份者缔造长 远、可持续的价值。" "友邦保险建基于2024年的卓越业绩，在2025年第一季保持增长势头，录得15亿美元的新业务价值，较 去年创新高的季度表现上升13%。我们能够持续及有规模地把握盈利性的新业务机遇，实有赖集团高度 多元化及强韧的业务模式，以及市场对友邦保险产品和服务与日俱增的需求。" "友邦保险的『最优秀代理』是我们增长策略的关键支柱，在2025年第一季所带来的新业务价值，占集 团整体超过75%。我们透过强劲和高质素的招聘持续提升我们的市场覆盖，支持整体活跃代理人数增长 8%。我们别树一帜的代理模式专注于建立长期客户关系，并由领先的数码平台所驱动，使得代理活跃 度及生产力进一步提升，同时保持多元化及具韧性的产品组合。" 友邦保险(01299)发布公告，于2025年第一季度，增长率按固定汇率基准 ...

Core Viewpoint - The company announced promising preclinical results for its novel FGFR2b-targeted antibody-drug conjugate (ADC) TST105, which demonstrates enhanced anti-tumor activity compared to existing ADCs in models of gastric and colorectal cancers [1][2]. Group 1: Clinical Research Findings - TST105 utilizes a site-specific conjugation technology and a novel topoisomerase I inhibitor as its payload, showing significantly improved anti-tumor efficacy in preclinical gastric and colorectal cancer models compared to ADCs using MMAE as a payload [1]. - In vitro studies indicate that TST105 exhibits specific cytotoxic effects on gastric and colorectal cancer cells, with an efficacy range of 0.3 nM to 0.4 nM, and demonstrates a stronger bystander effect compared to MMAE-based ADCs [2]. - In vivo pharmacological studies reveal that TST105 achieves a tumor growth inhibition (TGI) rate of 91.25% at a dose of 3 mg/kg in gastric cancer models, compared to 48.32% for Bema-MMAE, with an overall response rate (ORR) of 70% for TST105 versus 0% for Bema-MMAE [2]. Group 2: Industry Context and Future Prospects - The company expressed excitement about the transformative potential of TST105 in treating FGFR2b-overexpressing tumors, emphasizing its commitment to advancing this promising candidate into clinical development [3]. - The AACR 2025 conference, scheduled for April 25-30, 2025, in Chicago, serves as a significant platform for sharing advancements in cancer research, bringing together scientists, clinicians, and advocates to discuss the latest breakthroughs in oncology [3].